Hematology, Transfusion and Cell Therapy最新文献

{"title":"Comparison of nutritional risk index and body mass index in predicting survival outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study","authors":"Bruna Silvestre Françoso ,&nbsp;Isabela Laurêncio Schiavoni ,&nbsp;Thauany Nantes Guirao ,&nbsp;Barbara David dos Santos ,&nbsp;Thalita Cristina de Mello Costa ,&nbsp;Anderson Marliere Navarro ,&nbsp;Fabiola Traina ,&nbsp;Juliana Maria Faccioli Sicchieri","doi":"10.1016/j.htct.2026.106254","DOIUrl":"10.1016/j.htct.2026.106254","url":null,"abstract":"<div><h3>Introduction</h3><div>Allogeneic hematopoietic stem cell transplantation is a viable therapeutic option for several serious diseases however it is a high-risk procedure because it involves high-toxicity protocols with many adverse effects. Existing factors, such as the underlying disease and nutritional status, may influence the outcome. The objective of this study was to evaluate the Nutritional Risk Index as a prognostic tool by correlating it with body mass index, nutritional status, and clinical outcomes in patients undergoing hematopoietic stem cell transplantation.</div></div><div><h3>Methods</h3><div>This single center retrospective study was conducted collected sociodemographic, anthropometric, biochemical, and clinical data before conditioning and 30 days post-transplantation. Statistical analyses were performed using the Mann-Whitney test and Spearman's correlation. Overall survival was estimated using the Kaplan-Meier method, with comparisons conducted via the Gehan-Breslow-Wilcoxon test. A Cox Proportional Hazards regression analysis was employed to identify factors associated with mortality; variables demonstrating a p-value ≤0.20 in the univariate analysis were included in the multivariate model. For all analyses, statistical significance was defined as a p-value &lt;0.05.</div></div><div><h3>Results</h3><div>Seventy-seven participants were included, with an average age of 41 years. According to the nutritional risk index, the entire sample was classified as having severe nutritional risk. The body mass index showed that 6.4 % were malnourished, 19.4 % were obese, and 12.9 % had hypoalbuminemia. The estimated survival curve identified a significant difference for patients aged &lt;45 years with survival being significantly longer (p-value = 0.01). Higher albumin levels (≥3.5) after transplantation were associated with longer survival (p-value = 0.04). Sex, body mass index, albumin level before conditioning, and graft-versus-host disease showed no significant differences in terms of survival. Albumin levels ≥3.5 g/dL after transplantation were marginally associated with a lower mortality risk and malignant disease showed a trend toward increased mortality.</div></div><div><h3>Conclusion</h3><div>These findings underscore the clinical utility of prognostic indices, such as the Nutritional Risk Index and albumin levels, during the pre-transplant period, emphasizing the necessity for early nutritional interventions in hematopoietic stem cell transplantation patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106254"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells","authors":"Lena Avinery ,&nbsp;Danielle Regev ,&nbsp;Hazem Khamaisi ,&nbsp;Jacob Gopas ,&nbsp;Jamal Mahajna","doi":"10.1016/j.htct.2025.106240","DOIUrl":"10.1016/j.htct.2025.106240","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic myeloid leukemia is an adult leukemia, constituting 15 % of all leukemia diagnoses. The fundamental driver of disease pathogenesis is the Bcr/Abl fusion protein, characterized by dysregulated tyrosine kinase activity. Abl kinase inhibitors have become the mainstay of treatment, however, patients often develop resistance due to genetic alterations, particularly affecting the Bcr/Abl oncoprotein. The tumor microenvironment is also associated with acquired resistance to Abl kinase inhibitors in chronic myeloid leukemia.</div></div><div><h3>Methods</h3><div>The influence of hypoxic conditions on the development of chemoresistance to certain Abl kinase inhibitors was investigated in chronic myeloid leukemia.</div></div><div><h3>Results</h3><div>This study showed that hypoxia increased resistance to crizotinib, while imatinib resistance was modest. Both drugs effectively inhibited Bcr/Abl activity. Interestingly, the JAK1/2 inhibitor ruxolitinib further enhanced chemoresistance to crizotinib under hypoxic conditions. Hypoxia-inducible factor 1α (HIF1α) overexpression in JAK2 knockdown experiments confirmed their cooperative role in mediating crizotinib resistance. In addition, 2-methoxyestradiol, a non-estrogenic estradiol metabolite, restored crizotinib sensitivity under hypoxia and the combination of 2-methoxyestradiol with a JAK2 inhibitor showed promising results in overcoming crizotinib resistance.</div></div><div><h3>Conclusion</h3><div>In summary, this study shows the critical role of selective targeting of components of the HIF1α signaling pathway for the complete eradication of chronic myeloid leukemia cells.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106240"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025)","authors":"Amanda Pifano Soares Ferreira ,&nbsp;Cecília Emerick Mendes Vaz ,&nbsp;Laura Ferreira de Mesquita Ferraz ,&nbsp;Paulo de Mello Novita Teixeira ,&nbsp;Mariana Munari Magnus ,&nbsp;Clarissa de Miranda Fonseca ,&nbsp;Júlia Alvarenga Petrocchi ,&nbsp;Suzana de França Ribeiro Gonzaga ,&nbsp;Tathiana Rodrigues Peres Braz ,&nbsp;Rita de Cássia Rosário Cavalheiro ,&nbsp;Yara Andrea Pires Afonso Reina ,&nbsp;Sandra Regina Loggetto ,&nbsp;Lorena Lobo de Figueiredo Pontes ,&nbsp;Sílvia Maria Meira Magalhães ,&nbsp;Renato Sampaio Tavares ,&nbsp;Carlos Sérgio Chiattone ,&nbsp;Vânia Tietsche de Moraes Hungria ,&nbsp;Phillip Scheinberg ,&nbsp;Carmino Antônio de Souza ,&nbsp;Fernando Ferreira Costa ,&nbsp;Paula de Melo Campos","doi":"10.1016/j.htct.2026.106456","DOIUrl":"10.1016/j.htct.2026.106456","url":null,"abstract":"<div><div>Palliative care is, according to the World Health Organization (WHO), “a global ethical responsibility” and crucial to person-centered healthcare, for the relief of physical and psychological symptoms and social and spiritual suffering, impacting the improvement of the quality of life not only of pediatric and adult patients dealing with life-threatening illnesses, but also of their families. Despite the growing recognition of palliative care in the hematological setting and the increase in the number of publications on the subject, the available data are still scarce and limited. The objective of this consensus is to establish recommendations for the referral of pediatric and adult hematological patients to specialized palliative care teams and the possible integration of these two specialties.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106456"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147740008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of socioeconomic status on clinical presentation of multiple myeloma","authors":"Lívia Pessôa de Sant'Anna Coelho ,&nbsp;Renata Lyrio Rafael Baptista ,&nbsp;Gustavo de Almeida Buarque Bretas ,&nbsp;Ana Carolina Araujo ,&nbsp;Andrea Ribeiro Soares","doi":"10.1016/j.htct.2026.106256","DOIUrl":"10.1016/j.htct.2026.106256","url":null,"abstract":"<div><h3>Introduction</h3><div>The influence of socioeconomic status on cancer diagnosis, treatment, and outcomes has been studied for several decades. In multiple myeloma, many authors are investigating the impact of poverty and social inequalities, measured by indicators such as place of residence, number of residents, occupation, income and education, the incidence, stage and management of the disease, and survival, with controversial results. The aim of this study was to ambispectively analyze the association between socioeconomic status and clinical characteristics of multiple myeloma at presentation.</div></div><div><h3>Methods</h3><div>A total of 296 patients, diagnosed between 2015 and 2023 in three institutions in Rio de Janeiro, Brazil, were included. To assess the socioeconomic status, a social class questionnaire was administered to patients (or relatives, in the cases of death); information about educational level was collected from this interview and medical records and household income per capita were estimated, according to place of residence.</div></div><div><h3>Results</h3><div>Lower socioeconomic status was associated with delayed diagnosis, symptoms at presentation, advanced stage, poorer performance status, lower hemoglobin and higher calcium values.</div></div><div><h3>Conclusion</h3><div>These findings suggest a possible relationship between socioeconomic aspects and severity of multiple myeloma presentation in Brazil, and underscore the importance of shaping health policies to promote greater equity in cancer diagnosis and treatment access.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106256"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional capacity in sickle cell disease: A pilot study with 1-minute sit-to-stand test","authors":"Michele Barroso Thomaz ,&nbsp;Lucas Fernandes Suassuna ,&nbsp;Júlia Campos Fabri ,&nbsp;Isabela de Oliveira Araújo ,&nbsp;Júlia Carneiro Almeida ,&nbsp;Daniela de Oliveira Werneck Rodrigues","doi":"10.1016/j.htct.2025.106230","DOIUrl":"10.1016/j.htct.2025.106230","url":null,"abstract":"<div><h3>Background</h3><div>Sickle cell disease, the most prevalent monogenic recessive genetic disorder in the world, is characterized by two main pathogenic mechanisms: vaso-occlusion and hemolysis. These characteristics lead to reduced tolerance to physical exertion and, consequently, a reduced functional capacity which can be assessed using the one-minute sit-to-stand test. Complications from sickle cell disease result in poor quality of life, increased absenteeism from school and work, and impaired social interaction.</div></div><div><h3>Method</h3><div>Between January 2023 and April 2024, a pilot cross-sectional study was conducted with sickle cell disease patients aged from 18 to 60 years. The one-minute sit-to-stand test, Borg's perceived exertion scale, and the SF-36 quality of life questionnaire were utilized. Patients were monitored during the test. The sample was dichotomized based on test performance and SF-36 scores. Furthermore, clinical and demographic variables were analyzed.</div></div><div><h3>Main results</h3><div>Fifty-eight individuals participated in the final analysis. The mean age was 29.84 ± 11.20 years; 55.1 % were men, and 79.3 % identified themselves as Black or mixed race. The most prevalent genotype was hemoglobin SS (67.2 %), and 77.5 % were taking Hydroxyurea. The group with a better performance in the one-minute sit-to-stand test showed better quality of life as assessed using the SF-36 questionnaire.</div></div><div><h3>Conclusion</h3><div>Functional capacity is a significant factor in the autonomy and quality of life of patients with sickle cell disease. The one-minute sit-to-stand test is a low-cost and easily applicable test, which can contribute to the assessment of functional capacity in the routine follow-up of these patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106230"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data of autologous stem cell transplantation for patients with mantle cell lymphoma in Argentina","authors":"Martín Milanesio ,&nbsp;Mariano Berro ,&nbsp;Adriana Vitriu ,&nbsp;María Sol Jarchum ,&nbsp;Silvina Palmer ,&nbsp;Amalia Cerutti ,&nbsp;Evelyn Colombo ,&nbsp;Malena Rocca ,&nbsp;Lautaro Sardu ,&nbsp;Ana Laura Romero ,&nbsp;Micaela Quarchioni ,&nbsp;Fernando Warley ,&nbsp;Alejandra Banchieri ,&nbsp;Germán Wernicke ,&nbsp;María Marta Rivas ,&nbsp;José Trucco ,&nbsp;Leandro Castellanos ,&nbsp;Luciana Guanchiale ,&nbsp;Ana Romina Montivero ,&nbsp;Cecilia Foncuberta ,&nbsp;Ana Lisa Basquiera","doi":"10.1016/j.htct.2026.106449","DOIUrl":"10.1016/j.htct.2026.106449","url":null,"abstract":"<div><h3>Background</h3><div>For eligible patients with mantle cell lymphoma who respond to induction therapy, first-line consolidation with autologous hematopoietic progenitor cell transplantation remains a standard treatment. However, outcomes for these patients in Argentina have not been fully characterized. This paper aims to describe the factors linked to improved survival of patients with mantle cell lymphoma after transplantation in Argentina. In addition, the association between relapse within the first 24 months after transplant and overall survival was evaluated.</div></div><div><h3>Methods</h3><div>A retrospective, multicenter study was carried out. Patients over 18 years of age with a diagnosis of mantle cell lymphoma who received autologous hematopoietic progenitor cell transplantation from 2007–2023 at centers affiliated with the Argentine Group for Bone Marrow Transplantation and Cellular Therapy (GATMO-TC) were included. For the survival analysis, a landmark approach was utilized: overall survival was calculated from the date of progression for the group that relapsed within 24 months, and from the 24-month post-transplantation landmark for those who did not.</div></div><div><h3>Results</h3><div>One hundred and sixty-six patients from nine Argentine centers were included, 128 of whom were men (77%). The median age at transplantation was 58 years. Eighteen (11%) had blastoid morphology. The pretransplant status was complete response in 145 (87%) patients. With a median follow-up of 38.4 months, the median overall survival and progression-free survival were 102 and 48.8 months, respectively. In the multivariate analysis, the blastoid variant, an age ≥55 years, and a transplant comorbidity index ≥2 were independent predictors of survival.</div></div><div><h3>Conclusions</h3><div>&gt;70% achieved prolonged survival. Blastoid morphology, age older than 55 years, and comorbidities diminished outcomes after transplantation.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106449"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147600118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloid neoplasm with eosinophilia associated with FIP1L1–PDGFRA presenting as femoral avascular necrosis: a rare case report","authors":"Katia Gleicielly Frigotto ,&nbsp;Ingrid Caroline Rosa Diogo ,&nbsp;Pedro Guilherme Mol da Fonseca ,&nbsp;Victor Lopes de Abreu ,&nbsp;Júlia Rosa Dantas ,&nbsp;Paula Santos Barroso ,&nbsp;Juliana Bastos Torres ,&nbsp;Natália Laso Fonseca ,&nbsp;Vitor Ribeiro Gomes de Almeida Valviesse","doi":"10.1016/j.htct.2026.106258","DOIUrl":"10.1016/j.htct.2026.106258","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106258"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of vaccine-induced antibody responses against SARS-CoV-2 in multiple myeloma patients from the northeastern region of Mexico","authors":"Rosario Salazar-Riojas ,&nbsp;Dalila M. Alvarado-Navarro ,&nbsp;María L. Ruiz-de la Cruz ,&nbsp;Lorena Nefertiti Castro-Fuentes ,&nbsp;Karina E. Vazquez-Hernandez ,&nbsp;David Gomez-Almaguer ,&nbsp;Adrian G. Rosas-Taraco","doi":"10.1016/j.htct.2026.106448","DOIUrl":"10.1016/j.htct.2026.106448","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate immunoglobulin G antibody responses against Severe Acute Respiratory Syndrome Coronavirus 2 in multiple myeloma patients in the northeastern region of Mexico following different COVID-19 vaccination regimens.</div></div><div><h3>Methods</h3><div>This retrospective study included 33 multiple myeloma patients, and 28 healthy controls vaccinated with mRNA (BNT162b2, mRNA-1273) or adenovector (AZD1222) vaccines. Anti-spike receptor-binding domain (RBD) and anti-nucleocapsid immunoglobulin G levels were measured. Laboratory parameters, including monocyte and lymphocyte counts and serum-free light chains, were analyzed. Statistical comparisons used ANOVA, Kruskal-Wallis, and logistic regression.</div></div><div><h3>Results</h3><div>No significant differences in anti-spike receptor-binding domain immunoglobulin G levels were observed between multiple myeloma patients and healthy controls after one vaccine dose. Multiple myeloma patients who received ≥3 doses showed higher anti-spike receptor-binding domain immunoglobulin G levels compared to single-dose recipients. Anti-nucleocapsid antibodies (indicative of prior subclinical infection) were detected in 51.5% of multiple myeloma patients and correlated with elevated anti-spike receptor-binding domain levels. Patients in the third anti-spike immunoglobulin G quartile (10,427.9–23,954.0 AU/mL) had higher monocyte counts compared with patients in the lower quartiles. No correlations were found between anti-spike immunoglobulin G and lymphocyte counts, serum proteins, or gamma globulins. Abnormal kappa/lambda light chain ratios did not impair antibody responses in nucleocapsid-positive patients.</div></div><div><h3>Conclusion</h3><div>Multiple myeloma patients achieved comparable immunoglobulin G responses to healthy controls after one vaccine dose, with enhanced responses following ≥3 doses. Subclinical infections may augment humoral immunity. Elevated monocyte counts are indicative of innate immune activation following the administration of the vaccine. These findings support prioritizing booster doses for multiple myeloma patients despite immunosuppressive therapies.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106448"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute fibrinous and organizing pneumonia after bone marrow transplantation, an underrecognized, severe condition","authors":"Anita Cassoli Cortez ,&nbsp;Maria Cristina Nunez Seiwald ,&nbsp;Ana Rita Brito Medeiros da Fonseca ,&nbsp;Aliana Meneses Ferreira ,&nbsp;Gabriella Pogorzelski ,&nbsp;Leonardo de Abreu Testagrossa ,&nbsp;Yana Novis ,&nbsp;André Nathan Costa","doi":"10.1016/j.htct.2025.106238","DOIUrl":"10.1016/j.htct.2025.106238","url":null,"abstract":"<div><h3>Introduction</h3><div>Allogeneic bone marrow transplantation can lead to various pulmonary complications, including acute fibrinous organizing pneumonia. This condition is rare and presents with aggressive clinical features, distinct from other forms of organizing pneumonia, such as cryptogenic organizing pneumonia.</div></div><div><h3>Method</h3><div>A literature review using the PubMed, Embase, Lilacs, and Cochrane databases was conducted to analyze cases of acute fibrinous organizing pneumonia following transplantation focusing on clinical features, therapeutic approaches, and outcomes.</div></div><div><h3>Case Report</h3><div>The case of a 62-year-old female who developed acute fibrinous organizing pneumonia after transplantation for acute myeloid leukemia is presented. Despite an initial absence of infectious agents, parainfluenza virus was later identified in a bronchoalveolar lavage. The patient progressed to severe hypoxemic respiratory failure and was unresponsive to corticosteroids and rituximab, ultimately dying seven months post-transplant.</div></div><div><h3>Conclusion</h3><div>This is a rare and severe complication following allogeneic bone marrow transplantation. Early diagnosis, histopathological confirmation, and prompt initiation of corticosteroid therapy are critical for improving outcomes. Patients diagnosed before Day +100 generally have a better response to treatment and more favorable clinical outcomes. The need for a more effective and targeted treatment strategy remains an unmet challenge in managing this condition.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106238"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-dependent trade-offs among intravenous iron formulations for iron-deficiency anemia: a longitudinal systematic review and network meta-analysis","authors":"Francino Machado de Azevedo Filho,&nbsp;Mariana Millan Fachi,&nbsp;Layssa Andrade Oliveira,&nbsp;Haliton Alves de Oliveira Junior,&nbsp;Rosa Camila Lucchetta","doi":"10.1016/j.htct.2026.106435","DOIUrl":"10.1016/j.htct.2026.106435","url":null,"abstract":"<div><div>Intravenous iron formulations differ in benefits and risks that evolve across clinically relevant timepoints. A comprehensive network meta-analysis of randomized trials compared different intravenous iron formulations with oral iron and with each other. In addition to overall estimates, results are presented by predefined timepoints (4, 8, 12 and 24 weeks) for hemoglobin, ferritin, transferrin saturation, serious adverse events, and hypophosphatemia. Over 4-8 weeks, ferric carboxymaltose more consistently increased iron stores (ferritin/transferrin saturation) compared with the alternatives at the cost of a higher risk of hypophosphatemia. In 12-24 weeks, differences in iron stores attenuated and safety considerations became the main driver of choice, with ferric derisomaltose and iron sucrose generally favored when mineral safety is prioritized (e.g., for chronic kidney disease and inflammatory bowel disease). Effects on hemoglobin were broadly comparable between ferric carboxymaltose and ferric derisomaltose across most timepoints. These findings support conditional, scenario-specific decisions rather than a single ‘best’ formulation: ferric carboxymaltose when rapid repletion is critical and monitoring for hypophosphatemia is feasible; ferric derisomaltose and iron sucrose when safety predominates, or longer-term maintenance is planned. This windowed presentation facilitates pragmatic evidence translation for clinical decision-making while maintaining transparency through standard network meta-analysis diagnostics and certainty assessments.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106435"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147597374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}